Mammary Cell News Volume 15.22 | June 08 2023

    By
    Noshin Noorjahan
    -
    0
    46








    2023-06-08 | MCN 15.22


    Mammary Cell News by STEMCELL Technologies
    Vol. 15.22 – 8 June, 2023
    TOP STORY

    Identification of Fatty Acid Amide Hydrolase as a Metastasis Suppressor in Breast Cancer

    Scientists reported that the lipid-degrading enzyme fatty acid amide hydrolase was a predictor of long-term survival in patients with luminal breast cancer (BC), and that it blocked tumor progression and lung metastasis in cell and mouse models of BC.
    [Nature Communications]

    Full Article
    See how small molecules affect key signaling pathways in cancer research. Download your free wallchart now.
    PUBLICATIONSRanked by the impact factor of the journal

    Nicotinamide N-Methyltransferase Sustains a Core Epigenetic Program That Promotes Metastatic Colonization in Breast Cancer

    Researchers demonstrated that nicotinamide N-methyltransferase (NNMT) imprinted a basal genetic program into cancer cells, enhancing their plasticity. In line, NNMT expression was associated with poor clinical outcomes in patients with breast cancer.
    [EMBO Journal]

    AbstractPress ReleaseGraphical Abstract

    Breast Cancer Mutations HER2 V777L and PIK3CA H1047R Activate the p21-CDK4/6 –Cyclin D1 Axis Driving Tumorigenesis and Drug Resistance

    To study the effects of co-occurring HER2 and PIK3CA mutations, investigators bred genetically engineered mice with the HER2V777L; PIK3CAH1047R transgenes and studied the resulting breast cancers both in vivo as well as ex vivo using cancer organoids.
    [Cancer Research]

    Abstract

    17β-Estradiol Promotes Extracellular Vesicle Release and Selective miRNA Loading in ERα-Positive Breast Cancer

    Scientists reported that physiological doses of 17β-estradiol promoted extracellular vesicle (EV) secretion specifically from estrogen receptor–positive breast cancer cells via inhibition of miR-149-5p, hindering its regulatory activity on SP1, a transcription factor that regulated the EV biogenesis factor nSMase2.
    [Proceedings Of The National Academy Of Sciences Of The United States Of America]

    AbstractPress Release

    O-GlcNAcylation Promotes Topoisomerase IIα Catalytic Activity in Breast Cancer Chemoresistance

    The authors investigated the role of topoisomerase IIα (TOP2A) O-GlcNAcylation in breast cancer cells and patient tumor tissues. They demonstrated that elevated TOP2A, especially its O-GlcNAcylation, promoted breast cancer malignant progression and resistance to adriamycin.
    [EMBO Reports]

    AbstractGraphical Abstract

    A Bi-Steric mTORC1-Selective Inhibitor Overcomes Drug Resistance in Breast Cancer

    To address which mTOR kinase form was required for the survival of malignant cells, investigators used RMC-6272, a bi-steric molecule with a rapamycin-like moiety linked to an mTOR active-site inhibitor that displayed >25-fold selectivity for mTORC1 over mTORC2 substrates.
    [Oncogene]

    Full Article

    NUCB2/Nesfatin-1 Drives Breast Cancer Metastasis through the Up-Regulation of Cholesterol Synthesis via the mTORC1 Pathway

    ELISA was employed to measure the concentration of Nesfatin-1 in the serum of breast cancer patients and the control group. Database analysis suggested that nucleobindin-2 (NUCB2)/Nesfatin-1 might be acetylated in breast cancer.
    [Journal of Translational Medicine]

    Full Article

    Targeting CXCR4 Abrogates Resistance to Trastuzumab by Blocking Cell Cycle Progression and Synergizes with Docetaxel in Breast Cancer Treatment

    Immunofluorescent staining, confocal microscopy analysis, and immunoblotting were used to analyze C-X-C motif chemokine receptor 4 (CXCR4) expression. BrdU incorporation assays and flow cytometry were used to analyze dynamic CXCR4 expression.
    [Breast Cancer Research]

    Full Article

    Pak1 Pathway Hyper-Activation Mediates Resistance to Endocrine Therapy and CDK4/6 Inhibitors in ER+ Breast Cancer

    Researchers generated two estrogen receptor (ER) + breast cancer cell lines, T47D and MCF7, resistant to the combination of the ER antagonist fulvestrant and CDK4/6i abemaciclib, named T47D-FAR and MCF7-FAR.
    [npj Breast Cancer]

    Full Article

    NFYA Promotes Malignant Behavior of Triple-Negative Breast Cancer in Mice through the Regulation of Lipid Metabolism

    Scientists demonstrated that NFYAv1, a long-form variant, upregulated the transcription of essential lipogenic enzymes ACACA and FASN to enhance the malignant behavior of TNBC.
    [Communications Biology]

    Full Article

    Synergistic Cytotoxic Effects of an Extremely Low-Frequency Electromagnetic Field with Doxorubicin on MCF-7 Cell Line

    The authors investigated the potential cytotoxic effect of doxorubicin at low concentrations in combination with extremely low-frequency electromagnetic fields. The breast cancer cell line MCF-7 was examined for oxidative stress, cell cycle, and apoptosis.
    [Scientific Reports]

    Full Article

    Insulin-Like Growth Factor Binding Protein-3 Induces Senescence by Inhibiting Telomerase Activity in MCF-7 Breast Cancer Cells

    Investigators showd that insulin-like growth factor binding protein-3 induced cellular senescence via suppression of the telomerase activity, thereby inhibiting MCF-7 breast cancer cell proliferation.
    [Scientific Reports]

    Full Article

    Pharmacological Inhibition of Neuropeptide Y Receptors Y1 and Y5 Reduces Hypoxic Breast Cancer Migration, Proliferation, and Signaling

    Researchers measured the effects of neuropeptide Y (NPY) 1R and NPY5R antagonists in normoxia and hypoxia on migration, proliferation, invasion, and signaling in 2D and 3D models of breast cancer cell lines MDA-MB-231 and MCF7.
    [BMC Cancer]

    Full Article
    Listen to the Stem Cell Podcast episodes covering ISSCR 2022 sessions.
    REVIEWS

    Molecular Characterization and Landscape of Breast Cancer Models from a Multi-Omics Perspective

    The authors explore the molecular landscapes and characterization of breast cancer research models by comparing recently published multi-omics data and analysis.
    [Journal of Mammary Gland Biology and Neoplasia]

    Full Article
    INDUSTRY AND POLICY NEWS

    $3-Million Precision Prevention Progress Funding

    Breast Cancer Canada has announced a $3-million three-year funding for Princess Margaret Cancer Centre, University Health Network.
    [Breast Cancer Canada]

    Press Release

    FEATURED EVENT

    EMBO Workshop: Systems Approaches in Cancer

    June 26 – 30, 2023
    Split, Croatia

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scholar – Cancer Research

    The University of Tennessee Health Science Center – Memphis, Tennessee, United States

    Research Associate – Bioinformatics

    The University of British Columbia – Vancouver, British Columbia, Canada

    Research Associate – Breast Cancer

    Imperial College London – London, England, United Kingdom

    Postdoctoral Fellow – Immuno-Oncology Research

    Salk Institute – La Jolla, California, United States

    Postdoctoral Researcher – Comparative Breast Cancer Program

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter